ECM
LXEO icon

ExodusPoint Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

ExodusPoint Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$644K Buy
+112,172
New +$795K 0.01% 1122
2025
Q4 		– Sell
-27,380
Closed -$182K – 1834
2025
Q3 		$182K Buy
+27,380
New +$132K ﹤0.01% 1399
2024
Q1 		– Sell
-34,172
Closed -$459K – 1768
2023
Q4 		$459K Buy
+34,172
New +$424K ﹤0.01% 1054

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's LXEO Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Lexeo Therapeutics (LXEO) in Q1 2026: 112,172 shares worth $644K. The stake represents 0.01% of the portfolio and ranks #1122 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in LXEO as recently as Q3 2025.

ExodusPoint Capital Management first reported a position in LXEO in Q4 2023 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • ExodusPoint Capital Management held 112,172 shares of Lexeo Therapeutics worth $644K as of Q1 2026.
  • Lexeo Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
  • Lexeo Therapeutics made up 0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1122 holding.
  • ExodusPoint Capital Management first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.